Moderna's stock has surged 202% since August 18, driven by optimism over its experimental cancer vaccine, intismeran, which is co-developed with Merck. Analysts question whether the stock's sharp rise reflects genuine value, citing concerns that the valuation may be inflated by enthusiasm for the vaccine's potential. The vaccine, which shows promise in treating melanoma, faces challenges in expanding success to other cancers, leading some to argue that current stock prices assume broader efficacy than supported by evidence.
The rapid increase in Moderna's stock price has sparked debate among financial experts, who warn that the market may have overestimated the vaccine's commercial viability. While the vaccine's development with Merck highlights collaboration, critics suggest that the current stock valuation does not fully account for the risks and uncertainties associated with its potential applications beyond melanoma.